Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi C (Q57479764)
Jump to navigation
Jump to search
scientific article published on 01 December 1994
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi C |
scientific article published on 01 December 1994 |
Statements
Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica (English)
A Maresta
M Balducelli
L Cantini
A Casari
R Chioin
M Fabbri
A Fontanelli
P A Monici Preti
S Repetto
1 December 1994